Sumary of Long-term benefit of SABR for operable early-stage NSCLC shown in new study:
- A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects.
- The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.
- , professor of Thoracic and Cardiovascular Surgery — were published today in The Lancet Oncology.
- “After surgical resection, recovery may be prolonged and there can be significant loss of lung function depending on the amount of lung removed,” Chang said.
- “However, SABR functions as a non-invasive ‘knife’ to eliminate cancer with minimal side effects.
- Patients are treated in 30 minutes as an outpatient procedure, and they can return home or even work the same day after therapy is delivered.
- ” The study builds on the pooled analyses of two randomized studies (STARS and ROSEL trials), published in 2015, that investigated the advantages of SABR versus a surgical procedure called video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND).
- 31, 2017, and compared their results to propensity-matched patients undergoing surgery during the same time period.